Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?
Ennio Giulio FavalliSara MontiFrancesca IngegnoliSilvia BalduzziRoberto Felice CaporaliCarlomaurizio MontecuccoPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Our results reflected the attitude of patients with rheumatic diseases regarding the prevention of the infection while maintaining their long-term treatment regimens. The incidence and severity of COVID-19 in patients treated with targeted synthetic drugs or biologic DMARDs was not significantly different from that in the general population in the same region.